Contineum Therapeutics (CTNM) has initiated the process of becoming a publicly traded company on the Nasdaq stock exchange through an initial public offering (IPO).
The company describes itself as follows: “We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel, orally administered small molecule drugs. These drugs are designed to modulate biological pathways associated with specific disorders in the fields of neuroscience, inflammation, and immunology (NI&I). Our focus is on conditions where effective treatments are significantly lacking.”
Goldman Sachs & Co, Morgan Stanley (NYSE:MS), Stifel, and RBC Capital Markets have been appointed as lead underwriters for the offering.
source: tr.investing.com/ prepared by Melisa Beğiç
